Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

September 29, 2017

Primary Completion Date

April 5, 2018

Study Completion Date

April 5, 2018

Conditions
Solid Tumours
Interventions
DRUG

Treatment A - AZD1775 administered under fasted conditions

Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules. Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fasted conditions. The drug class of AZD1775 is Wee-1 kinase inhibitor.

DRUG

Treatment B - AZD1775 administered under fed conditions.

"Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules.~Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fed conditions.~The drug class of AZD1775 is Wee-1 kinase inhibitor."

Trial Locations (7)

33075

Research Site, Bordeaux

44805

Research Site, Saint-Herblain

1066 CX

Research Site, Amsterdam

1081 HV

Research Site, Amsterdam

6229 HX

Research Site, Maastricht

G12 0YN

Research Site, Glasgow

M20 4BX

Research Site, Manchester

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Quintiles, Inc.

INDUSTRY

lead

AstraZeneca

INDUSTRY